Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used

Dai Ogata, Kenjiro Namikawa, Masaki Otsuka, Jun Asai, Hisoshi Kato, Masahito Yasuda, Takeo Maekawa, Taku Fujimura, Junji Kato, Tatsuya Takenouchi, Kotaro Nagase, Masakazu Kawaguchi, Tatsuya Kaji, Yutaka Kuwatsuka, Yoshitsugu Shibayama, Toshihiro Takai, Mao Okumura, Yumi Kambayashi, Syusuke Yoshikawa, Naoya YamazakiTetsuya Tsuchida

Research output: Contribution to journalArticle

Abstract

Background: Cutaneous squamous cell carcinoma (cSCC) is the second most common type of skin cancer. Few patients with cSCC experience metastases, but the prognosis of advanced cSCC (acSCC) is dismal. Evidence regarding systemic therapy for acSCC is limited. Therefore, we aimed to determine the most effective systemic treatment for acSCC. Patients and methods: This retrospective study involved 16 Japanese institutions. We documented patient and tumour characteristics and disease course of patients with acSCC who received systemic therapy between 1st January 2006 and 31st December 2015. We compared the overall survival (OS) and progression-free survival (PFS) for (1) platinum versus non-platinum groups, (2) radiation plus chemotherapy first-line therapy (RCT) versus non-RCT groups and (3) platinum-based RCT versus non–platinum-based RCT groups. Results: Although the use of platinum-based systemic therapy was not associated with statistically significant improvements in PFS and OS, there were significant differences between the RCT and non-RCT groups (PFS: p < 0.001, OS: p = 0.003). In the subgroup analysis, RCT significantly prolonged PFS and OS in the nodal SCC (nSCC) group. For the RCT and non-RCT groups, the median OS was 110 and 14 months, respectively, and the 5-year OS rate was 54% and 21%, respectively. Conclusion: RCT could improve OS in patients with nSCC. However, further multicenter prospective studies are needed to establish evidence for superiority of RCT.

Original languageEnglish
Pages (from-to)108-117
Number of pages10
JournalEuropean Journal of Cancer
Volume127
DOIs
Publication statusPublished - Mar 2020

    Fingerprint

Keywords

  • Cemiplimab
  • Chemotherapy
  • Cisplatin
  • Cutaneous squamous cell carcinoma
  • EGFR inhibitor
  • Metastasis
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ogata, D., Namikawa, K., Otsuka, M., Asai, J., Kato, H., Yasuda, M., Maekawa, T., Fujimura, T., Kato, J., Takenouchi, T., Nagase, K., Kawaguchi, M., Kaji, T., Kuwatsuka, Y., Shibayama, Y., Takai, T., Okumura, M., Kambayashi, Y., Yoshikawa, S., ... Tsuchida, T. (2020). Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used. European Journal of Cancer, 127, 108-117. https://doi.org/10.1016/j.ejca.2019.12.018